Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

HPRG-induced downregulation of PlGF shows anticancer potential

Jan. 13, 2011

UCB claims new PI3K inhibitors

Jan. 13, 2011

Seattle Genetics and Pfizer join to develop anticancer antibody-drug conjugates

Jan. 12, 2011

Cylene Pharmaceuticals identifies novel protein kinase inhibitors

Jan. 12, 2011

Antimalarial artesunate has anticancer properties that can be enhanced by combination therapy

Jan. 12, 2011

Enrollment begins in phase III regorafenib trial in gastrointestinal stromal tumors

Jan. 11, 2011

Eusa Pharma obtains FDA priority review status for Erwinaze BLA

Jan. 11, 2011

Abraxis claims new proto-oncogene tyrosine-protein kinase Src inhibitors

Jan. 11, 2011

TopoTarget patents new NAmPRTase inhibitors

Jan. 11, 2011

Inhibition of HSP 90 is efficacious in MET-amplified tumor cells

Jan. 10, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...